The Global Impact of Emerging Infectious Diseases

Emerging infectious diseases have reshaped our world in ways that extend far beyond hospital walls. From the economic devastation of SARS to the ongoing challenge of drug-resistant tuberculosis, these diseases don’t just threaten individual health-they shake entire economies, overwhelm healthcare systems, and hit the world’s most vulnerable populations hardest.

The staggering burden of emerging diseases
Who bears the heaviest burden
Children at greatest risk
The poverty trap
The diverse world of emerging pathogens
Viruses: The rapid evolvers
Protozoans: Hidden threats
The growing threat of drug resistance
MDR-TB: A formidable challenge
XDR-TB: When options run out
Fighting back with new approaches
Understanding the bigger picture

The staggering burden of emerging diseases

When SARS emerged in 2002-2003, it infected at least 8,096 people and killed 774 worldwide. But the true cost went far beyond these numbers. The global economic loss approached $30-40 billion, with impacts rippling through tourism, travel, and retail sectors. Hong Kong’s tourist arrivals plummeted 68% just two months after WHO issued its warning, while Asia-Pacific airlines lost $6 billion in revenue.

The 2009 H1N1 pandemic told a similar story. The outbreak infected 1.3 million people globally and killed more than 18,000. Mexico’s tourism industry alone suffered a $2.8 billion hit, losing one million tourists over five months. The mere perception of risk devastated Mexico’s pork industry, with exports dropping over 60% to Japan and creating a $27 million trade deficit-despite the virus having no connection to consuming pork.

These outbreaks demonstrate how infectious diseases create economic shock waves that extend far beyond traditional health sectors, affecting everything from aviation to agriculture, and from small local businesses to multinational corporations.

Who bears the heaviest burden

Infectious diseases remain a leading cause of mortality and morbidity, particularly among children and the elderly in low- and middle-income countries. The inequality is stark-while high-income nations invest heavily in healthcare infrastructure and disease surveillance, resource-limited countries struggle with the dual burden of preventing disease and treating those already infected.

Children at greatest risk

For children younger than five in developing countries, infectious diseases cause between 50 and 80 percent of deaths. Diarrheal illnesses, respiratory infections, malaria, and vaccine-preventable diseases claim millions of young lives annually-deaths that are largely preventable with existing interventions.

Malaria alone affects an estimated 3.2 billion people at risk worldwide, with the geographic distribution of endemic malaria closely mirroring areas of extreme poverty. Children are particularly vulnerable, with severe anemia and hypoglycemia more commonly seen in young patients. In endemic regions, recurrent infections lead to chronic anemia and stunted development.

The poverty trap

Low-income countries face a vicious cycle. Poverty increases exposure to infectious diseases through inadequate sanitation, crowded living conditions, and limited healthcare access. These diseases then trap families in poverty by reducing productivity, increasing medical expenses, and forcing children out of school to care for sick relatives or earn income.

The 2013-2015 Ebola outbreak in West Africa illustrated this devastating cycle. The outbreak killed healthcare workers, reduced the entire healthcare workforce by 8% in Liberia and 23% in Sierra Leone, and led to an estimated 10,600 additional deaths from untreated HIV, tuberculosis, and malaria. Childhood vaccination coverage dropped 30%, and prenatal care collapsed.

The diverse world of emerging pathogens

Humans are affected by an impressive diversity of pathogens-1,407 species of viruses, bacteria, fungi, protozoa, and helminths are currently recognized. Of these, 177 species (13%) are considered emerging or reemerging. What’s particularly concerning is that 60.3% of emerging infectious diseases are zoonotic-originating from animals-with 71.8% of these coming from wildlife.

Viruses: The rapid evolvers

Viruses dominate emerging disease threats due to their remarkable ability to evolve and adapt. RNA viruses like influenza are particularly notorious. The 1918 influenza pandemic virus has evolved continuously for over 95 years through antigenic drift and shift, spawning new pandemics in 1957, 1968, and 2009. This continuous evolution forces us to develop new vaccine formulations annually.

Coronaviruses emerged from bats to cause SARS, MERS, and COVID-19. Nipah virus followed a similar path-emerging from bats, amplifying in intensively bred pigs, and then jumping to humans. Each jump required specific ecological and behavioral changes that brought humans into closer contact with animal reservoirs.

Protozoans: Hidden threats

While viruses grab headlines, protozoan parasites remain significant emerging threats, particularly in tropical and subtropical regions. Leishmania parasites cause leishmaniasis, characterized as a neglected tropical disease. What makes these parasites particularly concerning is their ability to harbor viruses themselves, which can increase disease severity and treatment failure rates.

The relationship between Leishmania and their RNA viruses demonstrates the complexity of emerging diseases. In certain endemic regions, up to 70% of Leishmania isolates carry these viruses, and their presence is associated with more severe disease and reduced treatment success.

The growing threat of drug resistance

Perhaps no challenge illustrates the urgency of emerging disease threats better than drug-resistant tuberculosis. The continuing spread of drug-resistant TB is one of the most urgent challenges facing global TB control.

MDR-TB: A formidable challenge

Multidrug-resistant tuberculosis (MDR-TB) refers to strains resistant to both isoniazid and rifampicin, the two most powerful first-line anti-TB drugs. In 2023, approximately 410,000 people developed MDR/RR-TB globally, responsible for about one-quarter of TB-related deaths. The treatment success rate remains alarmingly low-globally, only 63% of MDR-TB patients were cured in 2020, a significant improvement from 50% in 2012 but still far from acceptable.

The economic burden is crushing. Over 81% of households affected by drug-resistant TB experience catastrophic healthcare costs related to treatment expenses. These costs push families deeper into poverty, perpetuating the cycle of disease and economic hardship.

XDR-TB: When options run out

Extensively drug-resistant TB (XDR-TB) represents an even more frightening scenario. XDR-TB strains resist fluoroquinolones and second-line injectable drugs in addition to first-line medications. The global cure rate for XDR-TB is devastatingly low-only 20% are cured, while 44% die.

Mortality rates tell the grim story: approximately 40% for patients with MDR-TB and 60% for those with XDR-TB. The main drivers of this crisis are weak healthcare systems, improper treatment protocols that amplify resistance, and ongoing transmission in communities and healthcare facilities.

Fighting back with new approaches

Despite these challenges, there’s reason for hope. WHO released updated guidelines in 2025 introducing new all-oral, shorter treatment regimens for drug-resistant TB. These regimens, including the 6-month BPaLM combination, offer improved outcomes with reduced treatment duration and toxicity.

However, success depends on early identification of resistance patterns, properly designed treatment regimens, and addressing the socioeconomic factors that drive both disease transmission and poor treatment adherence. Community-based programs that allow patients to receive treatment at home while addressing barriers like poverty, malnutrition, and lack of social support have shown improved outcomes.

Understanding the bigger picture

Emerging infectious diseases reflect complex interactions between human behavior, environmental changes, and pathogen evolution. Recent research shows that socioeconomic factors like GDP, population density, and human development contribute more to infectious disease outbreaks than climatic factors alone.

Rapid urbanization, international travel, climate change, deforestation, and agricultural expansion all create new opportunities for pathogens to jump from animals to humans or to spread rapidly through populations. The COVID-19 pandemic demonstrated how quickly a novel pathogen can circle the globe, but it also showed that with coordinated action, scientific innovation, and public cooperation, we can mount effective responses.

Prevention remains our most powerful tool. The World Bank estimates that preventing six major outbreaks between 1997 and 2009 would have saved an average of $6.7 billion per year-far less than the cost of responding after diseases emerge.

What do you think? How can wealthy nations better support low-income countries in preventing and controlling emerging infectious diseases? What role should the private sector play in pandemic preparedness?

References

PDF 📄

Table of Contents

The staggering burden of emerging diseases 🔗

Who bears the heaviest burden 🔗

Children at greatest risk 🔗

The poverty trap 🔗

The diverse world of emerging pathogens 🔗

Viruses: The rapid evolvers 🔗

Protozoans: Hidden threats 🔗

The growing threat of drug resistance 🔗

MDR-TB: A formidable challenge 🔗

XDR-TB: When options run out 🔗

Fighting back with new approaches 🔗

Understanding the bigger picture 🔗